microdroplet-based PCR

NEW YORK (GenomeWeb News) – Myriad Genetics will adopt RainDance Technologies' microdroplet PCR-based target enrichment technology for use in a next-generation sequencing-based hereditary cancer panel test that Myriad is currently developing, the companies said today.

NEW YORK (GenomeWeb News) – RainDance Technologies today said that it has completed a collaboration with MLL Munich Leukemia Laboratory on the development of a panel for use in the sequence-based analysis of acute myeloid leukemia and myelodysplastic syndromes.

SUNY researchers are developing a droplet microfluidics device to extract mRNA from single cells, creating cDNA libraries in individual droplets for gene expression analysis.

RainDance's Sequence Enrichment application enhances SeqWright's targeted resequencing and whole-genome sequencing capabilities for studying disease pathways, cancer, and other areas of research, SeqWright said.

Ambry Genetics, which has a CAP-accredited and CLIA-certified laboratory, is using RainDance's RDT 1000 for micro-droplet PCR-based enrichment of target DNA for sequencing.

Under the partnership, Ambry will incorporate RainDance's RDT 1000 platform into sequence enrichment and targeted resequencing applications.

The study, published in Nature Biotechnology, found that RainDance Technologies' microdroplet-based PCR technology was more scalable than standard PCR for sequence enrichment, with comparable sensitivity and accuracy.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.